Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

doi:10.1200/JCO.2016.67.1875

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Jan 2017

Balsat Marie, Renneville Aline, Thomas Xavier, de Botton Stéphane, Caillot Denis, Marceau Alice, Lemasle Emilie, Marolleau Jean-Pierre, Nibourel Olivier, Berthon Céline, Raffoux Emmanuel, Pigneux Arnaud, Rodriguez Céline, Vey Norbert, Cayuela Jean-Michel, Hayette Sandrine, Braun Thorsten, Coudé Marie Magdeleine, Terre Christine, Celli-Lebras Karine, Dombret Hervé, Preudhomme Claude, Boissel Nicolas

Abstract excerpt

Purpose This study assessed the prognostic impact of postinduction NPM1-mutated ( NPM1m) minimal residual disease (MRD) in young adult patients (age, 18 to 60 years) with acute myeloid leukemia, and addressed the question of whether NPM1m MRD may be used as a predictive factor of allogeneic stem cell transplantation (ASCT) benefit. Patients and Methods Among 229 patients with NPM1m who were treated in the Acute...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multivariate Analysis

Share to Neoplasm, Residual

Share to Nuclear Proteins

Share to Nucleophosmin

Share to Remission Induction

Share to Stem Cell Transplantation

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 28056203
DOI: 10.1200/JCO.2016.67.1875

Genes

FLT3
NPM1
ELN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.PMID 28056203Read ↗

Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.Semantic proximity Read ↗

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.Semantic proximity Read ↗

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.Semantic proximity Read ↗

Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.Semantic proximity Read ↗

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.Semantic proximity Read ↗

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.Semantic proximity Read ↗

[Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].Semantic proximity Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.Semantic proximity Read ↗

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AMLSemantic proximity Read ↗

NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.Semantic proximity Read ↗

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.